PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen

First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen
2024-05-27
(Press-News.org) Osaka, Japan - A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models. This will be a world-first in-human clinical trial with [At-211] PSMA-5.

Prostate cancer is on the rise worldwide and is the most commonly diagnosed new cancer in men in Japan. Various treatments are offered for prostate cancer, but the prognosis is very poor when the disease is resistant to standard treatment and associated with multiple metastases.

In recent years, theranostics, which involves changing the radionuclide labeled to a compound that binds to a target, has been attracting attention as an integrated approach from cancer diagnostic imaging to therapy. Prostate-Specific Membrane Antigen (PSMA) is also gaining recognition as an innovative target for theranostics, enabling deployment from PET (positron emission tomography)-imaging based lesion detection to targeted radionuclide therapy. Furthermore, alpha irradiation from inside the body via intravenous injection enables treatment of metastases throughout the body.

In addition, astatine (At-211) is a nuclide that emits alpha rays with higher energy than conventional radiation and is expected to be effective even in patients exhibiting beta-ray treatment resistance. Since astatine can be produced using an accelerator, it enables domestic production without the need to import the radionuclide from abroad. A new cyclotron dedicated to its production will be installed at Osaka University with financial support by the Ministry of Economy and Industry, allowing for large-scale astatine supply.

Patients with castration-resistant prostate cancer with multiple metastases are treated with chemotherapy and other therapies. However, this comes with a significant number of side effects, and patients may become refractory to treatment in a short period. On the other hand, targeted radionuclide therapy rarely causes severe side effects, and treatments using short-range alpha radiation do not require hospitalization in a specialized room.

"Astatine can be manufactured domestically using an accelerator, and by establishing a manufacturing base, it is expected that a number of patients will be able to receive the treatment without hospitalization," says Tadashi Watabe, the principal investigator of the study. "In the future, it is expected that astatine will be used as a Japan-originated therapy for prostate cancer patients in need of treatment around the world."

###
About Osaka University
Osaka University was founded in 1931 as one of the seven imperial universities of Japan and is now one of Japan's leading comprehensive universities with a broad disciplinary spectrum. This strength is coupled with a singular drive for innovation that extends throughout the scientific process, from fundamental research to the creation of applied technology with positive economic impacts. Its commitment to innovation has been recognized in Japan and around the world. Now, Osaka University is leveraging its role as a Designated National University Corporation selected by the Ministry of Education, Culture, Sports, Science and Technology to contribute to innovation for human welfare, sustainable development of society, and social transformation.
Website: https://resou.osaka-u.ac.jp/en

END

[Attachments] See images for this press release:
First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen 2 First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen 3

ELSE PRESS RELEASES FROM THIS DATE:

Will generative AI change the way universities communicate?

2024-05-27
Since the launch of ChatGPT 3 in November 2022, we've been abuzz with talk of artificial intelligence: is it an unprecedented opportunity, or will it rob everyone of jobs and creativity? As we debate on social media (and perhaps use ChatGPT almost daily), generative AIs have also entered the arena of university communication. These tools—based on “Large Language Models” that were optimized for interactive communication—can indeed support, expand, and innovate university communication ...

Artificial Intelligence could help cure loneliness, says expert

2024-05-27
Artificial Intelligence (AI) technology could offer companionship to lonely people amid an international epidemic of loneliness, says a robotics expert. Tony Prescott, a professor of cognitive robotics at the University of Sheffield, argues in his new book The Psychology of Artificial Intelligence that ‘relationships with AIs could support people’ with forms of social interaction.. Loneliness has been found to seriously impair human health, and Professor Prescott makes a case that advances in AI technology could ...

Echidnapus identified from an ‘Age of Monotremes’

Echidnapus identified from an ‘Age of Monotremes’
2024-05-26
Published today in the Alcheringa: An Australasian Journal of Palaeontology, evidence of an ‘Age of Monotremes’ has been unearthed by a team of Australian scientists at the Australian Museum (AM), Museums Victoria and Australian Opal Centre. The findings were led by two renowned mammalogists, Honorary Associate of the Australian Museum, Professor Tim Flannery; and Professor Kris Helgen, Chief Scientist and Director of the Australian Museum Research Institute (AMRI). Found in the Lightning Ridge opal fields, NSW, the opalised jaws ...

Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular disease

2024-05-25
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.1 Unveiling the results today at the 61st ERA Congress, researchers presented the impressive secondary analysis from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial, a randomised trial comprising a participant pool of 17,604 individuals. Experts believe the study’s results offer hope for those affected by obesity, a condition known ...

New technique detects novel biomarkers for kidney diseases with nephrotic syndrome

2024-05-25
A groundbreaking study, presented today at the 61st ERA Congress, has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome.1 Using a hybrid technique, researchers identified anti-nephrin autoantibodies as a reliable biomarker for tracking disease progression, opening new avenues for personalised treatment approaches. Nephrotic syndrome, characterised by elevated protein levels in the urine, is linked to kidney diseases such as minimal change disease (MCD), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). The primary cause behind nephrotic syndrome is damage to podocytes, the ...

Political elites take advantage of anti-partisan protests to disrupt politics

Political elites take advantage of anti-partisan protests to disrupt politics
2024-05-24
Protest movements that reject political parties have an unintended consequence, according to new research from the University of Notre Dame: They empower savvy politicians who channel them to shake up the status quo. The findings provide a framework for understanding recent global political realignments and offer lessons for activists who want to make a meaningful impact. They are particularly relevant in an era when mass protests have become an increasingly common tool to voice dissent with powerful institutions and draw attention to overlooked issues ranging from climate and conflict ...

Tiny target discovered on RNA to short-circuit inflammation, UC Santa Cruz researchers find

Tiny target discovered on RNA to short-circuit inflammation, UC Santa Cruz researchers find
2024-05-24
UC Santa Cruz researchers have discovered a peptide in human RNA that regulates inflammation and may provide a new path for treating diseases such as arthritis and lupus. The team used a screening process based on the powerful gene-editing tool CRISPR to shed light on one of the biggest mysteries about our RNA–the molecule responsible for carrying out genetic information contained in our DNA. This peptide originates from within a long non-coding RNA (lncRNA) called LOUP. According to the researchers, ...

Charge your laptop in a minute? Supercapacitors can help; new research offers clues

2024-05-24
Imagine if your dead laptop or phone could charge in a minute or if an electric car could be fully powered in 10 minutes. While not possible yet, new research by a team of CU Boulder scientists could potentially lead to such advances.  Published today in the Proceedings of the National Academy of Sciences, researchers in Ankur Gupta’s lab discovered how tiny charged particles, called ions, move within a complex network of minuscule pores. The breakthrough could lead to the development of more efficient energy storage devices, such as supercapacitors, said Gupta, an assistant professor of chemical and biological engineering.  “Given the critical role ...

Scientists discover CO2 and CO ices in outskirts of solar system

2024-05-24
ORLANDO, May 24, 2024 – For the first time, carbon dioxide and carbon monoxide ices have been observed in the far reaches of our solar system on trans-Neptunian objects (TNOs). A research team, led by planetary scientists Mário Nascimento De Prá and Noemí Pinilla-Alonso from the University of Central Florida’s Florida Space Institute (FSI), made the findings by using the infrared spectral capabilities of the James Webb Space Telescope (JWST) to analyze the chemical composition of 59 trans-Neptunian objects and Centaurs. The pioneering study, published ...

Theory and experiment combine to shine a new light on proton spin

Theory and experiment combine to shine a new light on proton spin
2024-05-24
NEWPORT NEWS, VA – Nuclear physicists have long been working to reveal how the proton gets its spin. Now, a new method that combines experimental data with state-of-the-art calculations has revealed a more detailed picture of spin contributions from the very glue that holds protons together. It also paves the way toward imaging the proton’s 3D structure. The work was led by Joseph Karpie, a postdoctoral associate in the Center for Theoretical and Computational Physics (Theory Center) at the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility. He said that this decades-old mystery began with measurements of the sources of the proton’s spin in ...

LAST 30 PRESS RELEASES:

Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds

Innovative semaglutide hydrogel could reduce diabetes shots to once a month

Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests

Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions

Better cardiovascular health in early pregnancy may offset high genetic risk

Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer

Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer

IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing

Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors

Just how dangerous is Great Salt Lake dust? New research looks for clues

Maroulas appointed Associate Vice Chancellor, Director of AI Tennessee

New chickadee research finds cognitive skills impact lifespan

Cognitive behavioral therapy enhances brain circuits to relieve depression

Terasaki Institute awarded $2.3 Million grant from NIH for organ transplantation research using organs-on-a-chip technology

Atoms on the edge

Postdoc takes multipronged approach to muon detection

Mathematical proof: Five satellites needed for precise navigation

Scalable, multi-functional device lays groundwork for advanced quantum applications

Falling for financial scams? It may signal early Alzheimer’s disease

Integrating MRI and OCT for new insights into brain microstructure

Designing a normative neuroimaging library to support diagnosis of traumatic brain injury

Department of Energy announces $68 million in funding for artificial intelligence for scientific research

DOE, ORNL announce opportunity to define future of high-performance computing

Molecular simulations, supercomputing lead to energy-saving biomaterials breakthrough

Low-impact yoga and exercise found to help older women manage urinary incontinence

Genetic studies reveal new insights into cognitive impairment in schizophrenia

Researcher develops technology to provide cleaner energy and cleaner water

Expect the unexpected: nanoscale silver unveils intrinsic self-healing abilities

nTIDE September 2024 Jobs Report: Gains in employment for people with disabilities appear to level off after reducing gaps with non-disabled workers

Wiley enhances NMR Spectral Library Collection with extensive new databases

[Press-News.org] First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen